These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25137170)

  • 21. Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.
    Tuli G; Tessaris D; Einaudi S; De Sanctis L; Matarazzo P
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):288-292. PubMed ID: 28515029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer.
    Garrahy A; Hannon AM; Zia-Ul-Hussnain HM; Williams DJ; Thompson CJ
    Eur J Clin Pharmacol; 2018 Feb; 74(2):245-246. PubMed ID: 29147803
    [No Abstract]   [Full Text] [Related]  

  • 23. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C; Balbiano R; Caramello P; Roccatello D
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.
    Kai K; Tominaga N; Koitabashi K; Ichikawa D; Shibagaki Y
    CEN Case Rep; 2019 May; 8(2):112-118. PubMed ID: 30637666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA; Cranston IC
    BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Response to clinical case report: treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone].
    Santiago Pérez A; Runkle de la Vega I; Peña Pedrosa JA; Arias Fernández ML
    Farm Hosp; 2014 Nov; 38(6):496-7. PubMed ID: 25542666
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
    Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
    Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea].
    Callejas JL; Vallejo I; Palmero C; Fernández-Moyano A
    Med Clin (Barc); 2002 Apr; 118(15):599. PubMed ID: 12015955
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    Fleeman LM; Irwin PJ; Phillips PA; West J
    Aust Vet J; 2000 Dec; 78(12):825-30. PubMed ID: 11194468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolvaptan.
    Dubois EA; Rissmann R; Cohen AF
    Br J Clin Pharmacol; 2012 Jan; 73(1):9-11. PubMed ID: 21623874
    [No Abstract]   [Full Text] [Related]  

  • 32. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone.
    Decaux G; Genette F
    Br Med J (Clin Res Ed); 1981 Oct; 283(6299):1081-3. PubMed ID: 6794768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Syndrome of Inappropriate Antidiuresis.
    Moritz ML
    Pediatr Clin North Am; 2019 Feb; 66(1):209-226. PubMed ID: 30454744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolvaptan and urea in paediatric hyponatraemia.
    Veligratli F; Alexandrou D; Shah S; Amin R; Dattani M; Gan HW; Famuboni A; Lopez-Garcia C; Trompeter R; Bockenhauer D
    Pediatr Nephrol; 2024 Jan; 39(1):177-183. PubMed ID: 37466863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amiodarone-Induced Hyponatremia Masked by Tolvaptan in a Patient with an Implantable Left Ventricular Assist Device.
    Nakamura M; Sunagawa O; Kugai T; Kinugawa K
    Int Heart J; 2017 Dec; 58(6):1004-1007. PubMed ID: 29151494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with different initial doses of tolvaptan in SIADH.
    Barajas-Galindo DE; Vidal-Casariego A; Gómez-Hoyos E; Fernández-Martínez P; Guerra González M; Hernández-Moreno A; Alejo-Ramos M; Villar-Taibo R; Cano-Rodríguez I; Ballesteros-Pomar MD
    Nefrologia (Engl Ed); 2019; 39(6):672-674. PubMed ID: 31014551
    [No Abstract]   [Full Text] [Related]  

  • 37. Tolvaptan for hyponatremia.
    Hoorn EJ; Zietse R
    N Engl J Med; 2007 Mar; 356(9):961; author reply 962-3. PubMed ID: 17338052
    [No Abstract]   [Full Text] [Related]  

  • 38. The first case of levetiracetam-induced and tolvaptan-resistant hyponatremia.
    Arı H; Kahraman F; Acaban MB
    Turk Kardiyol Dern Ars; 2015 Apr; 43(3):284-7. PubMed ID: 25906002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH).
    Kenz S; Haas CS; Werth SC; Bohnet S; Brabant G
    Ann Oncol; 2011 Dec; 22(12):2696. PubMed ID: 22021821
    [No Abstract]   [Full Text] [Related]  

  • 40. How we define hyponatraemia?
    Cervellin G; Lippi G
    Eur J Clin Invest; 2015 Nov; 45(11):1219. PubMed ID: 26259932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.